MX2021011760A - Metodos para el tratamiento de canceres usando antisentido. - Google Patents
Metodos para el tratamiento de canceres usando antisentido.Info
- Publication number
- MX2021011760A MX2021011760A MX2021011760A MX2021011760A MX2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A MX 2021011760 A MX2021011760 A MX 2021011760A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antisense
- igf
- insulin
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825516P | 2019-03-28 | 2019-03-28 | |
| PCT/US2020/025217 WO2020198587A1 (en) | 2019-03-28 | 2020-03-27 | Methods for treating cancers using antisense |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011760A true MX2021011760A (es) | 2021-12-10 |
Family
ID=72609134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011760A MX2021011760A (es) | 2019-03-28 | 2020-03-27 | Metodos para el tratamiento de canceres usando antisentido. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220195440A1 (https=) |
| EP (1) | EP3946287A4 (https=) |
| JP (2) | JP2022527473A (https=) |
| AU (1) | AU2020244865A1 (https=) |
| CA (1) | CA3134969A1 (https=) |
| MX (1) | MX2021011760A (https=) |
| WO (1) | WO2020198587A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108291227A (zh) | 2015-10-14 | 2018-07-17 | 拜奥-帕斯控股股份有限公司 | 用于脂质体制剂的对乙氧基核酸 |
| AU2017325971A1 (en) | 2016-09-16 | 2019-04-11 | Bio-Path Holdings, Inc. | Combination therapy with liposomal antisense oligonucleotides |
| EA201992485A1 (ru) | 2017-04-19 | 2020-02-17 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования stat3 |
| EA201992490A1 (ru) | 2017-04-19 | 2020-03-03 | Байо-Пат Холдингз, Инк. | Р-этокси нуклеиновые кислоты для ингибирования bcl2 |
| WO2024077130A1 (en) * | 2022-10-05 | 2024-04-11 | Thomas Jefferson University | Methods and compositions for treating bladder cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541036B1 (en) * | 1997-05-29 | 2003-04-01 | Thomas Jefferson University | Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR) |
| WO2002027019A1 (en) * | 2000-09-29 | 2002-04-04 | The Johns Hopkins University School Of Medicine | Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents |
| NZ554831A (en) * | 2004-11-09 | 2009-10-30 | Schering Corp | Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level |
| EP1900825A1 (en) * | 2006-09-13 | 2008-03-19 | Rheinische Friedrich-Wilhelms-Universität Bonn | Sensitive and reproducible method for the determination of MGMT promoter methylation in clinical samples |
| CA2783665A1 (en) * | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2016164916A1 (en) * | 2015-04-10 | 2016-10-13 | Thomas Jefferson University | Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes |
| US10357509B2 (en) * | 2017-03-09 | 2019-07-23 | Thomas Jefferson University | Methods and compositions for treating cancers using antisense |
-
2020
- 2020-03-27 MX MX2021011760A patent/MX2021011760A/es unknown
- 2020-03-27 JP JP2021557634A patent/JP2022527473A/ja active Pending
- 2020-03-27 AU AU2020244865A patent/AU2020244865A1/en active Pending
- 2020-03-27 CA CA3134969A patent/CA3134969A1/en active Pending
- 2020-03-27 US US17/599,023 patent/US20220195440A1/en active Pending
- 2020-03-27 EP EP20778634.4A patent/EP3946287A4/en active Pending
- 2020-03-27 WO PCT/US2020/025217 patent/WO2020198587A1/en not_active Ceased
-
2025
- 2025-02-28 JP JP2025031086A patent/JP2025098027A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020244865A1 (en) | 2021-10-21 |
| US20220195440A1 (en) | 2022-06-23 |
| CA3134969A1 (en) | 2020-10-01 |
| EP3946287A1 (en) | 2022-02-09 |
| WO2020198587A1 (en) | 2020-10-01 |
| JP2025098027A (ja) | 2025-07-01 |
| JP2022527473A (ja) | 2022-06-02 |
| EP3946287A4 (en) | 2023-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010725A (es) | Metodos y composiciones para tratar canceres usando antisentido. | |
| MX2021011760A (es) | Metodos para el tratamiento de canceres usando antisentido. | |
| Zecha et al. | Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| JP2015516496A5 (https=) | ||
| US20180110978A1 (en) | Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields | |
| RU2014150569A (ru) | Конъюгат фотосенсибилизатора и хитозана и его применение | |
| ES2746276T3 (es) | Un aparato para controlar una sonda láser | |
| MX2020010676A (es) | Derivados de pladeniolida como agentes dirigidos al espliceosoma para tratar el cancer. | |
| EA201100626A1 (ru) | Лечение рака с помощью ионизирующего облучения и иммуноцитокинов | |
| MX2021005169A (es) | Metodos y composiciones para el tratamiento de carcinoma hepatocelular usando antisentido. | |
| MX2021005168A (es) | Metodos y composiciones para el tratamiento de cancer de mama usando antisentido. | |
| Deng et al. | Organic light-emitting diode therapy promotes longevity through the upregulation of SIRT1 in senescence-accelerated mouse prone 8 mice | |
| US20210283255A1 (en) | Reducing Damage From Chemotherapy And Increasing Cancer Kill Rates By Using Interweaved Low Dose Radiation | |
| CN114099975B (zh) | 一种胃部滞留胶囊、腰带及胃部神经刺激的方法 | |
| Tong et al. | Inhibiting human breast Cancer cells (MCF-7) with alternating Micro-current at intermediate frequency (ACIF) in vitro and in vivo | |
| RU2739196C2 (ru) | Способ инициации гибели опухолевых клеток янтарной кислотой и ВЧ- и СВЧ-энергией волнового излучения | |
| RU2606834C2 (ru) | Гель-фотосенсибилизатор для фотодинамической терапии | |
| KR101666838B1 (ko) | 흉터 치료 시스템 | |
| RU2325200C2 (ru) | Способ лазерного подавления роста и элиминации злокачественных образований | |
| Carroll | Photobiomodulation literature watch November 2021 | |
| von Hardenberg et al. | Therapeutic in vivo and in vitro effects of argon dye laser and hematoporphyrin derivative in lung cancer | |
| RU2819734C2 (ru) | Излучение внутриопухолевого альфа-излучателя и активация цитоплазматических рецепторов к внутриклеточному патогену | |
| Mao | Stem cells as a photosensitizer carrier to attack cancer cells for photodynamic therapy of breast cancer | |
| Matera et al. | Photoswitchable molecular prosthetics to photocontrol auditory neurons |